Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
New Zealand MMP Electoral System Faces Fresh Referendum Debate 
Mark Carney Jokes About Teleprompter, Takes Swipe at Trump 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
US Expands Social Media Vetting to Foreign Journalists Seeking Visas 
Trump Administration Weighs Executive Order on Vaccines and Autism Research 
SEC Moves to Dismiss Insider Trading Case Against Trump-Pardoned Terren Peizer 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
US Supreme Court Lets $655.5 Million Judgment Against Palestinian Authorities Stand During Appeal 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
25 Democratic-Led States Sue Trump Administration Over New Global Tariffs 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
U.S. Unseals Charges Against Five Alleged CJNG Leaders, Raises Reward for New Cartel Chief 
The United States is moving closer to naming a permanent leader for the Centers for Disease Control and Prevention, according to a top health official. Chris Klomp, chief counselor at the Department of Health and Human Services, expressed strong confidence following a series of interviews with potential candidates for the CDC director role.
"I'm very optimistic that we will select an excellent leader for that agency," Klomp stated during a Stat News health conference, signaling that the selection process is well underway.
The CDC has been operating under a succession of acting directors since former director Susan Monarez was dismissed last August after opposing vaccine policy changes proposed by Health Secretary Robert F. Kennedy Jr. Jim O'Neill briefly stepped in as acting director before being replaced by NIH Director Jay Bhattacharya following a leadership restructuring last month.
Kennedy's sweeping vaccine policy reforms have significantly disrupted the nation's public health infrastructure. A federal judge recently issued a temporary block on major components of those changes, including most of Kennedy's appointments to the CDC's vaccine advisory committee and proposed updates to childhood immunization recommendations. The HHS has since announced plans to appeal the ruling.
Adding further complexity, advisory committee member Dr. Robert Malone suggested via social media that the panel would be dissolved and reconstituted to sidestep a prolonged legal battle. However, an HHS spokesperson cautioned that any unofficial statements about next steps remain speculative until formally announced.
Legal pressure continues to mount. The American Academy of Pediatrics, which filed the original lawsuit challenging Kennedy's vaccine policies, made clear it will contest any committee restructuring that fails to meet proper legal and procedural standards.
As public health stakeholders await the appointment of a permanent CDC director, the agency's stability and its vaccine advisory framework remain central issues shaping the future of U.S. health policy.
